Special Issue

Upper Respiratory Infection: From Pathology to Novel Therapeutic Approaches

Message from the Guest Editor

Upper respiratory infections (URIs) represent a significant health burden worldwide, affecting millions annually and leading to substantial morbidity and economic costs. This Special Issue aims to delve into the complexities of URIs with a focused lens on rhinology. It will explore recent advances in biological therapies, pharmacological treatments, and innovative surgical techniques in managing allergic diseases and nasal polyposis. By bringing together cutting-edge research and clinical insights, this Issue seeks to provide a comprehensive overview of the current state and future directions in the diagnosis, management, and treatment of upper respiratory infections. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: Pathophysiology of Upper Respiratory Infections, Advances in Biological Therapies and Surgical Management.

Guest Editor

Dr. Puya Dehgani-Mobaraki

- 1. Associazione Naso Sano, Umbria Regional Registry of Volunteer Activities and Research, 06121 Perugia, Italy
- 2. The Hospital of Gubbio and Gualdo Tadino, 06024 Gubbio, Italy

Deadline for manuscript submissions

closed (31 May 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/205947

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).